Bluebird Bio INC (BLUE) Holder Capital International Investors Lowered Its Stake as Stock Price Declined

bluebird bio, Inc. (NASDAQ:BLUE) LogoInvestors sentiment decreased to 1.27 in 2019 Q2. Its down 0.43, from 1.7 in 2019Q1. It fall, as 30 investors sold BLUE shares while 63 reduced holdings. 35 funds opened positions while 83 raised stakes. 60.47 million shares or 0.32% more from 60.27 million shares in 2019Q1 were reported. Baillie Gifford & Com, a United Kingdom-based fund reported 4.22M shares. Alberta Invest Mgmt invested in 0.03% or 23,933 shares. Nuwave Inv Ltd Liability Company owns 158 shares. Biondo Advsr Limited Liability Com, Pennsylvania-based fund reported 1,695 shares. Exane Derivatives accumulated 0% or 5 shares. Fiera Capital Corporation holds 345,669 shares or 0.17% of its portfolio. Employees Retirement Association Of Colorado accumulated 0.01% or 7,118 shares. Price T Rowe Assoc Inc Md stated it has 1.42M shares or 0.03% of all its holdings. Virtu Ltd Liability Company accumulated 0.02% or 2,033 shares. Engineers Gate Manager Lp, a New York-based fund reported 3,331 shares. Ubs Asset Mgmt Americas holds 357,877 shares or 0% of its portfolio. Earnest Partners Limited Liability holds 0% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE) for 26 shares. 1,273 are owned by Benjamin F Edwards. Rocky Mountain Advisers Limited Liability Corp accumulated 18 shares. Bancorporation Of America De owns 505,274 shares.

Capital International Investors decreased its stake in Bluebird Bio Inc (BLUE) by 0.6% based on its latest 2019Q2 regulatory filing with the SEC. Capital International Investors sold 30,866 shares as the company’s stock declined 6.01% . The institutional investor held 5.09M shares of the health care company at the end of 2019Q2, valued at $647.32 million, down from 5.12 million at the end of the previous reported quarter. Capital International Investors who had been investing in Bluebird Bio Inc for a number of months, seems to be less bullish one the $5.80 billion market cap company. The stock increased 1.69% or $1.74 during the last trading session, reaching $104.85. About 801,134 shares traded or 32.14% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has declined 15.47% since September 13, 2018 and is downtrending. It has underperformed by 15.47% the S&P500.

Capital International Investors, which manages about $250.64B US Long portfolio, upped its stake in Noble Energy Inc (NYSE:NBL) by 5.42 million shares to 55.09 million shares, valued at $1.23 billion in 2019Q2, according to the filing. It also increased its holding in Asml Holding Nv (Usd) (NASDAQ:ASML) by 26,930 shares in the quarter, for a total of 6.41 million shares, and has risen its stake in Alphabet Inc Cl C.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on November, 7. They expect $-3.41 earnings per share, down 24.91 % or $0.68 from last year’s $-2.73 per share. After $-3.55 actual earnings per share reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts -3.94 % EPS growth.

More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Nasdaq.com which released: “UK Stocks-Factors to watch on Sept.10 – Nasdaq” on September 10, 2019, also Nasdaq.com with their article: “Diageo Gains on Innovation, Expansion Efforts: Can It Sustain? – Nasdaq” published on September 03, 2019, Nasdaq.com published: “4 Goldman Sachs Mutual Funds for Stellar Returns – Nasdaq” on September 04, 2019. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Nasdaq.com and their article: “Is it Time to Start Buying IBM Stock? – Nasdaq” published on August 27, 2019 as well as Nasdaq.com‘s news article titled: “Wall Street ends higher on trade, ECB stimulus hopes – Nasdaq” with publication date: September 12, 2019.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage

Among 2 analysts covering Bluebird Bio (NASDAQ:BLUE), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Bluebird Bio has $19100 highest and $122 lowest target. $149.67’s average target is 42.75% above currents $104.85 stock price. Bluebird Bio had 7 analyst reports since March 22, 2019 according to SRatingsIntel. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, August 6. Cantor Fitzgerald maintained bluebird bio, Inc. (NASDAQ:BLUE) on Friday, March 22 with “Hold” rating.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.